JP2016525352A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525352A5
JP2016525352A5 JP2016528640A JP2016528640A JP2016525352A5 JP 2016525352 A5 JP2016525352 A5 JP 2016525352A5 JP 2016528640 A JP2016528640 A JP 2016528640A JP 2016528640 A JP2016528640 A JP 2016528640A JP 2016525352 A5 JP2016525352 A5 JP 2016525352A5
Authority
JP
Japan
Prior art keywords
manganese
immunoligand
disease
ligand
expressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016528640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525352A (ja
JP6480926B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/063348 external-priority patent/WO2015011660A1/en
Publication of JP2016525352A publication Critical patent/JP2016525352A/ja
Publication of JP2016525352A5 publication Critical patent/JP2016525352A5/ja
Application granted granted Critical
Publication of JP6480926B2 publication Critical patent/JP6480926B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016528640A 2013-07-23 2014-07-23 タンパク質におけるフコシル化レベルを制御するための方法 Active JP6480926B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN3265CH2013 2013-07-23
IN3265/CHE/2013 2013-07-23
IN3262CH2013 2013-07-23
IN3262/CHE/2013 2013-07-23
PCT/IB2014/063348 WO2015011660A1 (en) 2013-07-23 2014-07-23 Methods for controlling fucosylation levels in proteins

Publications (3)

Publication Number Publication Date
JP2016525352A JP2016525352A (ja) 2016-08-25
JP2016525352A5 true JP2016525352A5 (https=) 2017-06-22
JP6480926B2 JP6480926B2 (ja) 2019-03-13

Family

ID=52392808

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016528640A Active JP6480926B2 (ja) 2013-07-23 2014-07-23 タンパク質におけるフコシル化レベルを制御するための方法

Country Status (19)

Country Link
US (2) US9856502B2 (https=)
EP (2) EP4282975A3 (https=)
JP (1) JP6480926B2 (https=)
KR (1) KR102062784B1 (https=)
CN (1) CN105392878A (https=)
AU (1) AU2014294618B2 (https=)
BR (1) BR112016001461A2 (https=)
CA (1) CA2926967C (https=)
CU (1) CU24312B1 (https=)
EA (1) EA201690269A1 (https=)
HK (1) HK1220228A1 (https=)
MX (1) MX2016001042A (https=)
NZ (1) NZ716182A (https=)
PE (1) PE20160218A1 (https=)
PH (1) PH12016500158A1 (https=)
SG (1) SG11201600067YA (https=)
TW (1) TWI621711B (https=)
WO (1) WO2015011660A1 (https=)
ZA (1) ZA201601113B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201001467A1 (ru) 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
PL3529274T3 (pl) * 2016-10-21 2024-09-09 Biocon Limited Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
AU2017360807B2 (en) * 2016-11-18 2024-11-28 Biocon Limited Rapid and efficient de-glycosylation of glycoproteins
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
BR112020019559A2 (pt) * 2018-03-26 2021-01-12 Amgen Inc. Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células
KR102742590B1 (ko) * 2018-04-20 2024-12-16 (주)셀트리온 당단백질의 푸코실레이션을 조절하는 방법
WO2020033827A1 (en) * 2018-08-10 2020-02-13 Genentech, Inc. Cell culture strategies for modulating protein glycosylation
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
EA202191352A1 (ru) * 2018-11-13 2021-08-11 Янссен Байотек, Инк. Контроль содержания микроэлементов-металлов во время продукции антител к cd38
JP7469593B2 (ja) * 2018-12-27 2024-04-17 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体を製造する方法
CN112779307B (zh) * 2021-01-11 2022-04-19 苏州药明生物技术有限公司 一种两阶段调节cho表达外源蛋白糖型的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
CA2282410A1 (en) * 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
ATE306810T1 (de) 2002-03-05 2005-11-15 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
US20090208500A1 (en) 2005-06-03 2009-08-20 Genentech, Inc. Method of producing antibodies with improved function
EP3026109B1 (en) 2005-12-08 2022-03-09 Amgen Inc. Improved production of glycoproteins using manganese
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
EA201001467A1 (ru) * 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
CA2763164A1 (en) * 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
BR112012025645A2 (pt) * 2010-04-07 2017-12-12 Momenta Pharmaceuticals Inc glicanos de alta manose.
US10059770B2 (en) * 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition

Similar Documents

Publication Publication Date Title
JP2016525352A5 (https=)
JP6963665B2 (ja) 細胞傷害誘導治療剤
CN106967172B (zh) 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
PE20210342A1 (es) Anticuerpos anti-sirpa y metodos de utilizacion de los mismos
RU2014130766A (ru) Гуманизированное анти-эпирегулин-антитело и противораковый терапевтический агент, содержащий указанное антитело, в качестве активного ингредиента
JP2012254083A5 (https=)
TW202342540A (zh) 用於癌之治療的細胞傷害誘導治療劑
JP2014520784A5 (https=)
KR20160056880A (ko) 항garp 단백질 항체와 그 용도
CN107531793A (zh) 对人类cd19具有专一性的抗体药剂和其用途
UA115533C2 (uk) ГУМАНІЗОВАНЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО, СПЕЦИФІЧНЕ ДО КОМПЛЕКСУ αβTCR/СD3 ЛЮДИНИ
JP2014515598A (ja) 二重特異性三鎖抗体様分子
TWI879694B (zh) 抗ctla-4抗體的用途
WO2022242703A1 (zh) 抗msln抗体及其应用
JP2023547380A (ja) 新規の抗lilrb2抗体および誘導体生成物
TW202304997A (zh) 新型抗cd4抗體
JP2015530989A5 (https=)
Schmied et al. An Fc-optimized CD133 antibody for induction of natural killer cell reactivity against colorectal cancer
CN116685604A (zh) 抗人msln的抗体及其用途
CN120769751A (zh) 抗原结合分子
Araki et al. A brief chronicle of antibody research and technological advances
CN103265631B (zh) 一种抗人crt单克隆抗体的重链和轻链可变区
CN116847863A (zh) 抗人cd22的单克隆抗体及其用途
RU2013139743A (ru) Гуманизированное моноклональное антитело, специфичное к синдекану-1
WO2024163530A2 (en) Novel anti-ccr4 antibodies and derivative products